Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Development trends for monoclonal antibody cancer therapeutics.

Reichert JM, Valge-Archer VE.

Nat Rev Drug Discov. 2007 May;6(5):349-56. Review.

PMID:
17431406
2.

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, Collins M, Carreno BM.

J Immunol. 2003 Jan 15;170(2):711-8.

3.

The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.

Valge-Archer VE, Osada H, Warren AJ, Forster A, Li J, Baer R, Rabbitts TH.

Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8617-21.

4.

Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.

McCaffrey PG, Kim PK, Valge-Archer VE, Sen R, Rao A.

Nucleic Acids Res. 1994 Jun 11;22(11):2134-42.

5.

Nuclear factor of activated T cells contains Fos and Jun.

Jain J, McCaffrey PG, Valge-Archer VE, Rao A.

Nature. 1992 Apr 30;356(6372):801-4.

PMID:
1533441
7.

Analysis of the AP-1 sites in the IL-2 promoter.

Jain J, Valge-Archer VE, Rao A.

J Immunol. 1992 Feb 15;148(4):1240-50.

PMID:
1737937
8.

Transformation of T lymphocytes by the v-fos oncogene.

Valge-Archer VE, de Villiers J, Sinskey AJ, Rao A.

J Immunol. 1990 Dec 15;145(12):4355-64.

PMID:
2124241

Supplemental Content

Loading ...
Support Center